The approaching influenza season will likely bring renewed debate about the usefulness of the neuraminidase inhibitors, a class of antiviral drugs approved for the chemoprophylaxis and treatment of influenza. The available approved formulations include oral oseltamivir (Tamiflu; Roche Pharmaceuticals), inhaled zanamivir (Relenza; GlaxoSmithKline), and intravenous peramivir (Rapivab; BioCryst Pharmaceuticals). All 3 drugs are perceived to have comparable efficacy, although because of its ease of administration, oseltamivir has been the best studied and is the most aggressively marketed and prescribed neuraminidase inhibitor in the United States and worldwide.
Louie JK, Lampiris H. Treating Influenza With Neuraminidase InhibitorsWhat Is the Evidence?. JAMA Intern Med. 2015;175(12):1899-1900. doi:10.1001/jamainternmed.2015.5747